HKD 3.34
(-1.47%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 585.85 Million CNY | 18.98% |
2022 | 846.54 Million CNY | 51.42% |
2021 | 559.06 Million CNY | 83.95% |
2020 | 303.92 Million CNY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 121.82 Million CNY | -57.26% |
2024 Q2 | 121.82 Million CNY | 0.0% |
2023 Q2 | 242.59 Million CNY | 0.0% |
2023 FY | 1 Billion CNY | 18.98% |
2023 Q3 | 306.49 Million CNY | 26.34% |
2023 Q1 | 242.59 Million CNY | -52.83% |
2023 Q4 | 285.02 Million CNY | -7.01% |
2022 FY | 846.54 Million CNY | 51.42% |
2022 Q3 | 514.26 Million CNY | 0.0% |
2022 Q4 | 514.26 Million CNY | 0.0% |
2021 FY | 559.06 Million CNY | 83.95% |
2020 FY | 303.92 Million CNY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Uni-Bio Science Group Limited | 325.05 Million HKD | -80.236% |
CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 20.75% |